$ADMA
ADMA BIOLOGICS, INC.

2024 Q3 Form 10-Q Financial Statement

#000114036124036432 Filed on August 08, 2024

View on sec.gov

Income Statement

Concept 2024 Q3 2024 Q2 2023 Q2
Revenue $119.8M $107.2M $60.12M
YoY Change 78.13% 78.29% 77.33%
Cost Of Revenue $60.18M $49.74M $43.43M
YoY Change 41.19% 14.52% 66.18%
Gross Profit $59.66M $57.45M $16.69M
YoY Change 142.0% 244.24% 114.82%
Gross Profit Margin 49.78% 53.6% 27.76%
Selling, General & Admin $18.56M $16.61M $14.25M
YoY Change 26.04% 16.57% 19.02%
% of Gross Profit 31.11% 28.91% 85.37%
Research & Development $412.0K $560.0K $1.403M
YoY Change -30.86% -60.09% 60.67%
% of Gross Profit 0.69% 0.97% 8.41%
Depreciation & Amortization $1.900M $1.900M $1.900M
YoY Change 0.0% 0.0% 26.67%
% of Gross Profit 3.18% 3.31% 11.38%
Operating Expenses $20.02M $18.25M $17.16M
YoY Change 25.39% 6.34% 1.29%
Operating Profit $39.64M $39.20M -$473.1K
YoY Change 356.39% -8386.39% -94.84%
Interest Expense -$2.833M -$3.334M $6.299M
YoY Change -144.28% -152.93% 37.75%
% of Operating Profit -7.15% -8.5%
Other Income/Expense, Net -$2.889M -$3.350M -$5.898M
YoY Change -52.79% -43.2% 28.48%
Pretax Income $36.75M $35.85M -$6.371M
YoY Change 1329.92% -662.75% -53.72%
Income Tax $800.0K $3.800M $0.00
% Of Pretax Income 2.18% 10.6%
Net Earnings $35.91M $32.06M -$6.371M
YoY Change 1299.93% -603.27% -53.72%
Net Earnings / Revenue 29.96% 29.91% -10.6%
Basic Earnings Per Share $0.15 $0.14 -$0.03
Diluted Earnings Per Share $0.15 $0.13 -$0.03
COMMON SHARES
Basic Shares Outstanding 233.1M 231.8M 222.3M
Diluted Shares Outstanding 244.8M 242.2M 222.7M

Balance Sheet

Concept 2024 Q3 2024 Q2 2023 Q2
SHORT-TERM ASSETS
Cash & Short-Term Investments $86.71M $88.24M $62.51M
YoY Change 16.86% 41.16% 19.27%
Cash & Equivalents $86.70M $88.20M $62.51M
Short-Term Investments
Other Short-Term Assets $9.545M $5.524M $5.219M
YoY Change 87.16% 5.85% -3.36%
Inventory $171.8M $179.8M $161.8M
Prepaid Expenses
Receivables $50.10M $30.10M $36.73M
Other Receivables $0.00 $0.00 $0.00
Total Short-Term Assets $318.2M $303.7M $266.2M
YoY Change 16.26% 14.07% 19.51%
LONG-TERM ASSETS
Property, Plant & Equipment $53.69M $54.33M $56.31M
YoY Change -2.04% -3.52% 2.46%
Goodwill $3.500M $3.500M $3.500M
YoY Change 0.0% 0.0% -0.84%
Intangibles $485.0K $479.0K $655.7K
YoY Change 1.7% -26.95% -52.17%
Long-Term Investments
YoY Change
Other Assets $5.819M $5.221M $6.289M
YoY Change -13.15% -16.98% 67.44%
Total Long-Term Assets $72.43M $72.71M $76.78M
YoY Change -3.81% -5.31% 3.54%
TOTAL ASSETS
Total Short-Term Assets $318.2M $303.7M $266.2M
Total Long-Term Assets $72.43M $72.71M $76.78M
Total Assets $390.6M $376.4M $343.0M
YoY Change 11.93% 9.73% 15.52%
SHORT-TERM LIABILITIES
YoY Change
Accounts Payable $16.02M $14.18M $12.08M
YoY Change 47.63% 17.33% 6.12%
Accrued Expenses $25.41M $26.58M $27.53M
YoY Change -9.88% -3.46% 103.75%
Deferred Revenue $143.0K $1.130M $142.8K
YoY Change 0.12% 691.13% 0.0%
Short-Term Debt $0.00 $0.00 $0.00
YoY Change
Long-Term Debt Due
YoY Change
Total Short-Term Liabilities $44.90M $44.20M $41.95M
YoY Change 7.31% 5.36% 49.45%
LONG-TERM LIABILITIES
Long-Term Debt $101.3M $131.1M $140.3M
YoY Change -28.64% -6.58% 0.36%
Other Long-Term Liabilities $375.0K $390.0K $449.5K
YoY Change -13.72% -13.24% 20.22%
Total Long-Term Liabilities $375.0K $390.0K $449.5K
YoY Change -13.72% -13.24% 20.22%
TOTAL LIABILITIES
Total Short-Term Liabilities $44.90M $44.20M $41.95M
Total Long-Term Liabilities $375.0K $390.0K $449.5K
Total Liabilities $158.7M $188.1M $196.3M
YoY Change -19.66% -4.14% 7.52%
SHAREHOLDERS EQUITY
Retained Earnings -$420.5M -$456.4M -$491.2M
YoY Change -13.94% -7.08% 8.94%
Common Stock $24.00K $23.00K $22.45K
YoY Change 6.21% 2.44% 14.35%
Preferred Stock
YoY Change
Treasury Stock (at cost)
YoY Change
Treasury Stock Shares
Shareholders Equity $231.9M $188.3M $146.8M
YoY Change
Total Liabilities & Shareholders Equity $390.6M $376.4M $343.0M
YoY Change 11.93% 9.73% 15.52%

Cashflow Statement

Concept 2024 Q3 2024 Q2 2023 Q2
OPERATING ACTIVITIES
Net Income $35.91M $32.06M -$6.371M
YoY Change 1299.93% -603.27% -53.72%
Depreciation, Depletion And Amortization $1.900M $1.900M $1.900M
YoY Change 0.0% 0.0% 26.67%
Cash From Operating Activities $25.03M $45.65M -$6.059M
YoY Change 108.91% -853.39% -52.78%
INVESTING ACTIVITIES
Capital Expenditures $1.098M $2.365M $872.6K
YoY Change 46.4% 171.02% -122.15%
Acquisitions
YoY Change
Other Investing Activities
YoY Change
Cash From Investing Activities -$1.098M -$2.365M -$872.6K
YoY Change 46.4% 171.02% -77.85%
FINANCING ACTIVITIES
Cash Dividend Paid
YoY Change
Common Stock Issuance & Retirement, Net
YoY Change
Debt Paid & Issued, Net
YoY Change
Cash From Financing Activities -25.47M -362.0K 240.1K
YoY Change -6311.46% -250.76% -175.26%
NET CHANGE
Cash From Operating Activities 25.03M 45.65M -6.059M
Cash From Investing Activities -1.098M -2.365M -872.6K
Cash From Financing Activities -25.47M -362.0K 240.1K
Net Change In Cash -1.537M 42.92M -6.691M
YoY Change -113.2% -741.42% -60.85%
FREE CASH FLOW
Cash From Operating Activities $25.03M $45.65M -$6.059M
Capital Expenditures $1.098M $2.365M $872.6K
Free Cash Flow $23.93M $43.28M -$6.931M
YoY Change 113.09% -724.42% -22.04%

Facts In Submission

Frame Concept Type Concept / XBRL Key Value Unit
CY2024Q2 us-gaap Inventory Raw Materials
InventoryRawMaterials
56985000
CY2023Q4 us-gaap Inventory Raw Materials
InventoryRawMaterials
52999000
CY2024Q2 us-gaap Inventory Work In Process
InventoryWorkInProcess
55069000
CY2023Q4 us-gaap Inventory Work In Process
InventoryWorkInProcess
49621000
CY2024Q2 us-gaap Inventory Finished Goods
InventoryFinishedGoods
67756000
CY2023Q4 us-gaap Inventory Finished Goods
InventoryFinishedGoods
70286000
CY2024Q2 us-gaap Inventory Net
InventoryNet
179810000
CY2023Q4 us-gaap Inventory Net
InventoryNet
172906000
dei Security Exchange Name
SecurityExchangeName
NASDAQ
dei Amendment Flag
AmendmentFlag
false
dei Current Fiscal Year End Date
CurrentFiscalYearEndDate
--12-31
dei Document Fiscal Year Focus
DocumentFiscalYearFocus
2024
dei Document Fiscal Period Focus
DocumentFiscalPeriodFocus
Q2
dei Entity Central Index Key
EntityCentralIndexKey
0001368514
CY2023Q4 us-gaap Debt Instrument Variable Interest Rate Type Extensible Enumeration
DebtInstrumentVariableInterestRateTypeExtensibleEnumeration
http://fasb.org/us-gaap/2024#SecuredOvernightFinancingRateSofrMember
us-gaap Debt Instrument Variable Interest Rate Type Extensible Enumeration
DebtInstrumentVariableInterestRateTypeExtensibleEnumeration
http://fasb.org/us-gaap/2024#SecuredOvernightFinancingRateSofrMember
CY2023 us-gaap Debt Instrument Variable Interest Rate Type Extensible Enumeration
DebtInstrumentVariableInterestRateTypeExtensibleEnumeration
http://fasb.org/us-gaap/2024#SecuredOvernightFinancingRateSofrMember
CY2024Q2 us-gaap Commitments And Contingencies
CommitmentsAndContingencies
CY2023Q4 us-gaap Commitments And Contingencies
CommitmentsAndContingencies
CY2024Q2 adma Accounts Receivable Allowance For Contractual Credits And Doubtful Accounts
AccountsReceivableAllowanceForContractualCreditsAndDoubtfulAccounts
200000
CY2023Q4 adma Accounts Receivable Allowance For Contractual Credits And Doubtful Accounts
AccountsReceivableAllowanceForContractualCreditsAndDoubtfulAccounts
100000
CY2024Q2 us-gaap Goodwill
Goodwill
3500000
CY2023Q4 us-gaap Goodwill
Goodwill
3500000
us-gaap Goodwill Impairment Loss
GoodwillImpairmentLoss
0
CY2024Q2 us-gaap Goodwill Impairment Loss
GoodwillImpairmentLoss
0
us-gaap Goodwill Impairment Loss
GoodwillImpairmentLoss
0
CY2023Q2 us-gaap Goodwill Impairment Loss
GoodwillImpairmentLoss
0
CY2023Q2 us-gaap Impairment Of Long Lived Assets Held For Use
ImpairmentOfLongLivedAssetsHeldForUse
0
us-gaap Impairment Of Long Lived Assets Held For Use
ImpairmentOfLongLivedAssetsHeldForUse
0
CY2024Q2 us-gaap Impairment Of Long Lived Assets Held For Use
ImpairmentOfLongLivedAssetsHeldForUse
0
us-gaap Impairment Of Long Lived Assets Held For Use
ImpairmentOfLongLivedAssetsHeldForUse
0
CY2024Q2 us-gaap Net Income Loss
NetIncomeLoss
32062000
us-gaap Net Income Loss
NetIncomeLoss
49868000
CY2024Q2 us-gaap Weighted Average Number Of Shares Outstanding Basic
WeightedAverageNumberOfSharesOutstandingBasic
232417645
us-gaap Weighted Average Number Of Shares Outstanding Basic
WeightedAverageNumberOfSharesOutstandingBasic
230646246
CY2024Q2 us-gaap Earnings Per Share Basic
EarningsPerShareBasic
0.14
us-gaap Earnings Per Share Basic
EarningsPerShareBasic
0.22
CY2024Q2 us-gaap Weighted Average Number Of Shares Outstanding Basic
WeightedAverageNumberOfSharesOutstandingBasic
232417645
us-gaap Weighted Average Number Of Shares Outstanding Basic
WeightedAverageNumberOfSharesOutstandingBasic
230646246
CY2024Q2 us-gaap Weighted Average Number Of Diluted Shares Outstanding
WeightedAverageNumberOfDilutedSharesOutstanding
242167072
us-gaap Weighted Average Number Of Diluted Shares Outstanding
WeightedAverageNumberOfDilutedSharesOutstanding
239645940
CY2024Q2 us-gaap Earnings Per Share Diluted
EarningsPerShareDiluted
0.13
us-gaap Earnings Per Share Diluted
EarningsPerShareDiluted
0.21
us-gaap Antidilutive Securities Excluded From Computation Of Earnings Per Share Amount
AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount
0
CY2024Q2 us-gaap Antidilutive Securities Excluded From Computation Of Earnings Per Share Amount
AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount
0
adma Dilutive Securities Excluded From Computation Of Earnings Per Share Amount Shares
DilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmountShares
0
CY2023Q2 adma Dilutive Securities Excluded From Computation Of Earnings Per Share Amount Shares
DilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmountShares
0
us-gaap Antidilutive Securities Excluded From Computation Of Earnings Per Share Amount
AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount
26962867
CY2023Q4 us-gaap Unrecognized Tax Benefits
UnrecognizedTaxBenefits
0
CY2024Q2 us-gaap Unrecognized Tax Benefits
UnrecognizedTaxBenefits
0
us-gaap Tax Adjustments Settlements And Unusual Provisions
TaxAdjustmentsSettlementsAndUnusualProvisions
0
us-gaap Tax Adjustments Settlements And Unusual Provisions
TaxAdjustmentsSettlementsAndUnusualProvisions
0
CY2023Q2 us-gaap Tax Adjustments Settlements And Unusual Provisions
TaxAdjustmentsSettlementsAndUnusualProvisions
0
CY2024Q2 us-gaap Tax Adjustments Settlements And Unusual Provisions
TaxAdjustmentsSettlementsAndUnusualProvisions
0
CY2024Q2 us-gaap Finite Lived Intangible Assets Gross
FiniteLivedIntangibleAssetsGross
5532000
CY2024Q2 us-gaap Finite Lived Intangible Assets Accumulated Amortization
FiniteLivedIntangibleAssetsAccumulatedAmortization
5053000
CY2024Q2 us-gaap Finite Lived Intangible Assets Net
FiniteLivedIntangibleAssetsNet
479000
CY2023Q4 us-gaap Finite Lived Intangible Assets Gross
FiniteLivedIntangibleAssetsGross
5217000
CY2023Q4 us-gaap Finite Lived Intangible Assets Accumulated Amortization
FiniteLivedIntangibleAssetsAccumulatedAmortization
4718000
CY2023Q4 us-gaap Finite Lived Intangible Assets Net
FiniteLivedIntangibleAssetsNet
499000
us-gaap Finite Lived Intangible Assets Period Increase Decrease
FiniteLivedIntangibleAssetsPeriodIncreaseDecrease
300000
CY2024Q2 us-gaap Amortization Of Intangible Assets
AmortizationOfIntangibleAssets
100000
CY2023Q2 us-gaap Amortization Of Intangible Assets
AmortizationOfIntangibleAssets
200000
us-gaap Amortization Of Intangible Assets
AmortizationOfIntangibleAssets
300000
us-gaap Amortization Of Intangible Assets
AmortizationOfIntangibleAssets
400000
CY2024Q2 us-gaap Finite Lived Intangible Assets Amortization Expense Remainder Of Fiscal Year
FiniteLivedIntangibleAssetsAmortizationExpenseRemainderOfFiscalYear
44000
CY2024Q2 us-gaap Finite Lived Intangible Assets Amortization Expense Next Rolling Twelve Months
FiniteLivedIntangibleAssetsAmortizationExpenseNextRollingTwelveMonths
132000
CY2024Q2 us-gaap Finite Lived Intangible Assets Amortization Expense Rolling Year Two
FiniteLivedIntangibleAssetsAmortizationExpenseRollingYearTwo
132000
CY2024Q2 us-gaap Finite Lived Intangible Assets Amortization Expense Rolling Year Three
FiniteLivedIntangibleAssetsAmortizationExpenseRollingYearThree
122000
CY2024Q2 us-gaap Finite Lived Intangible Assets Amortization Expense Rolling Year Four
FiniteLivedIntangibleAssetsAmortizationExpenseRollingYearFour
51000
CY2024Q2 adma Accrued Rebates Current
AccruedRebatesCurrent
4338000
CY2023Q4 adma Accrued Rebates Current
AccruedRebatesCurrent
16608000
CY2024Q2 us-gaap Accrued Professional Fees Current
AccruedProfessionalFeesCurrent
8373000
CY2023Q4 us-gaap Accrued Professional Fees Current
AccruedProfessionalFeesCurrent
5954000
CY2024Q2 us-gaap Accrued Bonuses Current
AccruedBonusesCurrent
2377000
CY2023Q4 us-gaap Accrued Bonuses Current
AccruedBonusesCurrent
4961000
CY2024Q2 us-gaap Interest Payable Current
InterestPayableCurrent
3775000
CY2023Q4 us-gaap Interest Payable Current
InterestPayableCurrent
546000
CY2024Q2 adma Accrued Testing Current
AccruedTestingCurrent
488000
CY2023Q4 adma Accrued Testing Current
AccruedTestingCurrent
282000
CY2024Q2 us-gaap Accrued Income Taxes Current
AccruedIncomeTaxesCurrent
2834000
CY2023Q4 us-gaap Accrued Income Taxes Current
AccruedIncomeTaxesCurrent
0
CY2024Q2 us-gaap Accrued Salaries Current
AccruedSalariesCurrent
3249000
CY2023Q4 us-gaap Accrued Salaries Current
AccruedSalariesCurrent
2203000
CY2024Q2 us-gaap Other Accrued Liabilities Current
OtherAccruedLiabilitiesCurrent
2292000
CY2023Q4 us-gaap Other Accrued Liabilities Current
OtherAccruedLiabilitiesCurrent
2365000
CY2024Q2 us-gaap Accrued Liabilities And Other Liabilities
AccruedLiabilitiesAndOtherLiabilities
27726000
CY2023Q4 us-gaap Accrued Liabilities And Other Liabilities
AccruedLiabilitiesAndOtherLiabilities
32919000
CY2024Q2 us-gaap Debt Instrument Unamortized Discount
DebtInstrumentUnamortizedDiscount
3926000
CY2023Q4 us-gaap Debt Instrument Unamortized Discount
DebtInstrumentUnamortizedDiscount
4406000
CY2024Q2 us-gaap Senior Long Term Notes
SeniorLongTermNotes
131074000
CY2023Q4 us-gaap Senior Long Term Notes
SeniorLongTermNotes
130594000
CY2023Q4 adma Senior Notes Payable Before Debt Discount
SeniorNotesPayableBeforeDebtDiscount
135000000
CY2023Q4 us-gaap Preferred Stock Capital Shares Reserved For Future Issuance
PreferredStockCapitalSharesReservedForFutureIssuance
10000000
CY2024Q2 us-gaap Preferred Stock Capital Shares Reserved For Future Issuance
PreferredStockCapitalSharesReservedForFutureIssuance
10000000
CY2024Q2 us-gaap Preferred Stock Par Or Stated Value Per Share
PreferredStockParOrStatedValuePerShare
0.0001
CY2023Q4 us-gaap Preferred Stock Par Or Stated Value Per Share
PreferredStockParOrStatedValuePerShare
0.0001
CY2024Q2 us-gaap Preferred Stock Shares Outstanding
PreferredStockSharesOutstanding
0
CY2023Q4 us-gaap Preferred Stock Shares Outstanding
PreferredStockSharesOutstanding
0
CY2024Q2 us-gaap Common Stock Shares Authorized
CommonStockSharesAuthorized
300000000
CY2023Q4 us-gaap Common Stock Shares Authorized
CommonStockSharesAuthorized
300000000
CY2024Q2 us-gaap Common Stock Par Or Stated Value Per Share
CommonStockParOrStatedValuePerShare
0.0001
CY2023Q4 us-gaap Common Stock Par Or Stated Value Per Share
CommonStockParOrStatedValuePerShare
0.0001
CY2024Q2 us-gaap Common Stock Shares Outstanding
CommonStockSharesOutstanding
233026736
CY2023Q4 us-gaap Common Stock Shares Outstanding
CommonStockSharesOutstanding
226063032
CY2024Q2 us-gaap Class Of Warrant Or Right Outstanding
ClassOfWarrantOrRightOutstanding
31407217
CY2024Q2 us-gaap Common Stock Capital Shares Reserved For Future Issuance
CommonStockCapitalSharesReservedForFutureIssuance
35566047
CY2024Q1 us-gaap Class Of Warrant Or Right Number Of Securities Called By Warrants Or Rights
ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights
4000000
CY2024Q1 us-gaap Common Stock Shares Issued
CommonStockSharesIssued
1977514
CY2024Q1 us-gaap Class Of Warrant Or Right Number Of Securities Called By Warrants Or Rights
ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights
169651
CY2024Q1 us-gaap Common Stock Shares Issued
CommonStockSharesIssued
85784
CY2024Q1 us-gaap Class Of Warrant Or Right Number Of Securities Called By Warrants Or Rights
ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights
34800
CY2024Q2 us-gaap Share Based Compensation
ShareBasedCompensation
2863000
CY2023Q2 us-gaap Share Based Compensation
ShareBasedCompensation
1637000
us-gaap Share Based Compensation
ShareBasedCompensation
5004000
us-gaap Share Based Compensation
ShareBasedCompensation
2747000
adma Plasma Supply Agreement Term
PlasmaSupplyAgreementTerm
P10Y
CY2019Q2 us-gaap Research And Development Expense
ResearchAndDevelopmentExpense
800000
CY2024Q2 adma Number Of Fda Licensed Plasma Collection Facilities
NumberOfFDALicensedPlasmaCollectionFacilities
10
us-gaap Number Of Operating Segments
NumberOfOperatingSegments
2
CY2024Q2 us-gaap Revenue From Contract With Customer Excluding Assessed Tax
RevenueFromContractWithCustomerExcludingAssessedTax
107191000
CY2024Q2 us-gaap Cost Of Revenue
CostOfRevenue
49738000
CY2024Q2 us-gaap Operating Income Loss
OperatingIncomeLoss
39201000
CY2024Q2 us-gaap Nonoperating Income Expense
NonoperatingIncomeExpense
-3350000
CY2024Q2 us-gaap Income Loss From Continuing Operations Before Income Taxes Extraordinary Items Noncontrolling Interest
IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest
35851000
CY2024Q2 us-gaap Depreciation And Amortization
DepreciationAndAmortization
2047000
CY2024Q2 us-gaap Assets
Assets
376399000
CY2023Q2 us-gaap Revenue From Contract With Customer Excluding Assessed Tax
RevenueFromContractWithCustomerExcludingAssessedTax
60123000
CY2023Q2 us-gaap Cost Of Revenue
CostOfRevenue
43433000
CY2023Q2 us-gaap Operating Income Loss
OperatingIncomeLoss
-473000
CY2023Q2 us-gaap Nonoperating Income Expense
NonoperatingIncomeExpense
-5898000
CY2023Q2 us-gaap Income Loss From Continuing Operations Before Income Taxes Extraordinary Items Noncontrolling Interest
IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest
-6371000
CY2023Q2 us-gaap Assets
Assets
343027000
CY2023Q2 us-gaap Depreciation And Amortization
DepreciationAndAmortization
2098000
us-gaap Revenue From Contract With Customer Excluding Assessed Tax
RevenueFromContractWithCustomerExcludingAssessedTax
189066000
us-gaap Cost Of Revenue
CostOfRevenue
92505000
us-gaap Operating Income Loss
OperatingIncomeLoss
61022000
us-gaap Nonoperating Income Expense
NonoperatingIncomeExpense
-6770000
us-gaap Income Loss From Continuing Operations Before Income Taxes Extraordinary Items Noncontrolling Interest
IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest
54252000
us-gaap Segment Expenditure Addition To Long Lived Assets
SegmentExpenditureAdditionToLongLivedAssets
4413000
us-gaap Depreciation And Amortization
DepreciationAndAmortization
4161000
us-gaap Revenue From Contract With Customer Excluding Assessed Tax
RevenueFromContractWithCustomerExcludingAssessedTax
117037000
us-gaap Cost Of Revenue
CostOfRevenue
83834000
us-gaap Operating Income Loss
OperatingIncomeLoss
-1286000
us-gaap Nonoperating Income Expense
NonoperatingIncomeExpense
-11874000
us-gaap Income Loss From Continuing Operations Before Income Taxes Extraordinary Items Noncontrolling Interest
IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest
-13160000
us-gaap Segment Expenditure Addition To Long Lived Assets
SegmentExpenditureAdditionToLongLivedAssets
2817000
us-gaap Depreciation And Amortization
DepreciationAndAmortization
4131000
CY2024Q2 us-gaap Revenue From Contract With Customer Excluding Assessed Tax
RevenueFromContractWithCustomerExcludingAssessedTax
107191000
CY2023Q2 us-gaap Revenue From Contract With Customer Excluding Assessed Tax
RevenueFromContractWithCustomerExcludingAssessedTax
60123000
us-gaap Revenue From Contract With Customer Excluding Assessed Tax
RevenueFromContractWithCustomerExcludingAssessedTax
189066000
us-gaap Revenue From Contract With Customer Excluding Assessed Tax
RevenueFromContractWithCustomerExcludingAssessedTax
117037000
CY2024Q2 us-gaap Operating Lease Expense
OperatingLeaseExpense
600000
CY2023Q2 us-gaap Operating Lease Expense
OperatingLeaseExpense
600000
us-gaap Operating Lease Expense
OperatingLeaseExpense
1200000
us-gaap Operating Lease Expense
OperatingLeaseExpense
1200000
CY2023Q2 us-gaap Operating Lease Payments
OperatingLeasePayments
600000
CY2024Q2 us-gaap Operating Lease Payments
OperatingLeasePayments
600000
us-gaap Operating Lease Payments
OperatingLeasePayments
1200000
us-gaap Operating Lease Payments
OperatingLeasePayments
1100000
CY2024Q2 adma Operating And Financing Lease Liability
OperatingAndFinancingLeaseLiability
10300000
CY2023Q4 adma Operating And Financing Lease Liability
OperatingAndFinancingLeaseLiability
10800000
CY2024Q2 us-gaap Operating Lease Weighted Average Remaining Lease Term1
OperatingLeaseWeightedAverageRemainingLeaseTerm1
P7Y2M12D
CY2024Q2 us-gaap Lessee Operating Lease Liability Payments Remainder Of Fiscal Year
LesseeOperatingLeaseLiabilityPaymentsRemainderOfFiscalYear
1204000
CY2024Q2 us-gaap Lessee Operating Lease Liability Payments Due Next Twelve Months
LesseeOperatingLeaseLiabilityPaymentsDueNextTwelveMonths
2421000
CY2024Q2 us-gaap Lessee Operating Lease Liability Payments Due Year Two
LesseeOperatingLeaseLiabilityPaymentsDueYearTwo
2157000
CY2024Q2 us-gaap Lessee Operating Lease Liability Payments Due Year Three
LesseeOperatingLeaseLiabilityPaymentsDueYearThree
2041000
CY2024Q2 us-gaap Lessee Operating Lease Liability Payments Due Year Four
LesseeOperatingLeaseLiabilityPaymentsDueYearFour
2088000
CY2024Q2 us-gaap Lessee Operating Lease Liability Payments Due Year Five
LesseeOperatingLeaseLiabilityPaymentsDueYearFive
2109000
CY2024Q2 us-gaap Lessee Operating Lease Liability Payments Due After Year Five
LesseeOperatingLeaseLiabilityPaymentsDueAfterYearFive
4041000
CY2024Q2 us-gaap Lessee Operating Lease Liability Payments Due
LesseeOperatingLeaseLiabilityPaymentsDue
16061000
CY2024Q2 us-gaap Lessee Operating Lease Liability Undiscounted Excess Amount
LesseeOperatingLeaseLiabilityUndiscountedExcessAmount
5737000
CY2024Q2 us-gaap Operating Lease Liability Current
OperatingLeaseLiabilityCurrent
1142000
CY2024Q2 us-gaap Operating Lease Liability Noncurrent
OperatingLeaseLiabilityNoncurrent
9182000
CY2024Q2 us-gaap Income Tax Expense Benefit
IncomeTaxExpenseBenefit
3800000
us-gaap Income Tax Expense Benefit
IncomeTaxExpenseBenefit
4400000
us-gaap Effective Income Tax Rate Continuing Operations
EffectiveIncomeTaxRateContinuingOperations
0.081
us-gaap Effective Income Tax Rate Reconciliation At Federal Statutory Income Tax Rate
EffectiveIncomeTaxRateReconciliationAtFederalStatutoryIncomeTaxRate
0.21
us-gaap Interest Paid Net
InterestPaidNet
3843000
us-gaap Interest Paid Net
InterestPaidNet
9274000
us-gaap Income Taxes Paid
IncomeTaxesPaid
1550000
us-gaap Income Taxes Paid
IncomeTaxesPaid
0
adma Equipment Acquired Reflected In Accounts Payable And Accrued Liabilities
EquipmentAcquiredReflectedInAccountsPayableAndAccruedLiabilities
207000
adma Equipment Acquired Reflected In Accounts Payable And Accrued Liabilities
EquipmentAcquiredReflectedInAccountsPayableAndAccruedLiabilities
511000
adma Warrants Issued In Connection With Notes Payable
WarrantsIssuedInConnectionWithNotesPayable
0
adma Warrants Issued In Connection With Notes Payable
WarrantsIssuedInConnectionWithNotesPayable
5595000
CY2024Q2 ecd Non Rule10b51 Arr Adopted Flag
NonRule10b51ArrAdoptedFlag
false
CY2024Q2 ecd Rule10b51 Arr Adopted Flag
Rule10b51ArrAdoptedFlag
false
CY2024Q2 ecd Non Rule10b51 Arr Trmntd Flag
NonRule10b51ArrTrmntdFlag
false
CY2024Q2 ecd Rule10b51 Arr Trmntd Flag
Rule10b51ArrTrmntdFlag
false

Files In Submission

Name View Source Status
0001140361-24-036432-index-headers.html Edgar Link pending
0001140361-24-036432-index.html Edgar Link pending
0001140361-24-036432.txt Edgar Link pending
0001140361-24-036432-xbrl.zip Edgar Link pending
adma-20240630.xsd Edgar Link pending
ef20029669_10q.htm Edgar Link pending
ef20029669_ex31-1.htm Edgar Link pending
ef20029669_ex31-2.htm Edgar Link pending
ef20029669_ex32-1.htm Edgar Link pending
ef20029669_ex32-2.htm Edgar Link pending
Financial_Report.xlsx Edgar Link pending
MetaLinks.json Edgar Link pending
R1.htm Edgar Link pending
R10.htm Edgar Link pending
R11.htm Edgar Link pending
R12.htm Edgar Link pending
R13.htm Edgar Link pending
R14.htm Edgar Link pending
R15.htm Edgar Link pending
R16.htm Edgar Link pending
R17.htm Edgar Link pending
R18.htm Edgar Link pending
R19.htm Edgar Link pending
R2.htm Edgar Link pending
R20.htm Edgar Link pending
R21.htm Edgar Link pending
R22.htm Edgar Link pending
R23.htm Edgar Link pending
R24.htm Edgar Link pending
R25.htm Edgar Link pending
R26.htm Edgar Link pending
R27.htm Edgar Link pending
R28.htm Edgar Link pending
R29.htm Edgar Link pending
R3.htm Edgar Link pending
R30.htm Edgar Link pending
R31.htm Edgar Link pending
R32.htm Edgar Link pending
R33.htm Edgar Link pending
R34.htm Edgar Link pending
R35.htm Edgar Link pending
R36.htm Edgar Link pending
R37.htm Edgar Link pending
R38.htm Edgar Link pending
R39.htm Edgar Link pending
R4.htm Edgar Link pending
R40.htm Edgar Link pending
adma-20240630_def.xml Edgar Link unprocessable
adma-20240630_lab.xml Edgar Link unprocessable
adma-20240630_pre.xml Edgar Link unprocessable
FilingSummary.xml Edgar Link unprocessable
ef20029669_10q_htm.xml Edgar Link completed
R41.htm Edgar Link pending
R42.htm Edgar Link pending
R43.htm Edgar Link pending
R44.htm Edgar Link pending
R45.htm Edgar Link pending
R46.htm Edgar Link pending
R47.htm Edgar Link pending
R48.htm Edgar Link pending
R49.htm Edgar Link pending
R5.htm Edgar Link pending
R50.htm Edgar Link pending
R51.htm Edgar Link pending
R52.htm Edgar Link pending
R53.htm Edgar Link pending
R54.htm Edgar Link pending
R55.htm Edgar Link pending
R56.htm Edgar Link pending
R57.htm Edgar Link pending
R58.htm Edgar Link pending
R6.htm Edgar Link pending
R7.htm Edgar Link pending
R8.htm Edgar Link pending
R9.htm Edgar Link pending
report.css Edgar Link pending
Show.js Edgar Link pending
adma-20240630_cal.xml Edgar Link unprocessable